WO2000047222A3 - Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation - Google Patents

Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation Download PDF

Info

Publication number
WO2000047222A3
WO2000047222A3 PCT/AT2000/000023 AT0000023W WO0047222A3 WO 2000047222 A3 WO2000047222 A3 WO 2000047222A3 AT 0000023 W AT0000023 W AT 0000023W WO 0047222 A3 WO0047222 A3 WO 0047222A3
Authority
WO
WIPO (PCT)
Prior art keywords
influenza virus
nasal
oral administration
virus vaccine
inactivated influenza
Prior art date
Application number
PCT/AT2000/000023
Other languages
English (en)
French (fr)
Other versions
WO2000047222A2 (de
Inventor
Noel Barrett
Otfried Kistner
Marijan Gerencer
Friedrich Dorner
Original Assignee
Baxter Vaccine Ag
Noel Barrett
Otfried Kistner
Marijan Gerencer
Friedrich Dorner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Vaccine Ag, Noel Barrett, Otfried Kistner, Marijan Gerencer, Friedrich Dorner filed Critical Baxter Vaccine Ag
Priority to AT00903423T priority Critical patent/ATE395929T1/de
Priority to AU25253/00A priority patent/AU770923B2/en
Priority to DE50015170T priority patent/DE50015170D1/de
Priority to US09/913,400 priority patent/US6635246B1/en
Priority to EP00903423A priority patent/EP1144001B1/de
Priority to DK00903423T priority patent/DK1144001T3/da
Publication of WO2000047222A2 publication Critical patent/WO2000047222A2/de
Publication of WO2000047222A3 publication Critical patent/WO2000047222A3/de
Priority to US11/027,936 priority patent/US7052701B2/en
Priority to US11/365,836 priority patent/US20060147468A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Abstract

Die Erfindung betrifft die Verwendung einer Zusammensetzung, enthaltend inaktiviertes Influenzavirus-Antigen und Aluminium als Adjuvans zur Herstellung einer Influenzavirus-Vakzine zur nasalen oder oralen Verabreichung zur Prophylaxe gegen Influenzavirus-Infektionen. Insbesondere ist die Vakzine dazu geeignet, die mukosale IgA- und systemische IgG-Immunantwort zu induzieren.
PCT/AT2000/000023 1999-02-11 2000-02-01 Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation WO2000047222A2 (de)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AT00903423T ATE395929T1 (de) 1999-02-11 2000-02-01 Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
AU25253/00A AU770923B2 (en) 1999-02-11 2000-02-01 Inactivated influenza virus vaccine for nasal or oral administration
DE50015170T DE50015170D1 (de) 1999-02-11 2000-02-01 Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
US09/913,400 US6635246B1 (en) 1999-02-11 2000-02-01 Inactivated influenza virus vaccine for nasal or oral application
EP00903423A EP1144001B1 (de) 1999-02-11 2000-02-01 Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
DK00903423T DK1144001T3 (da) 1999-02-11 2000-02-01 Inaktiveret influenzavirusvaccine til nasal eller oral indgivelse
US11/027,936 US7052701B2 (en) 1999-02-11 2005-01-04 Inactivated influenza virus vaccine for nasal or oral application
US11/365,836 US20060147468A1 (en) 1999-02-11 2006-03-02 Inactivated influenza virus vaccine for nasal or oral application

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0019499A AT407958B (de) 1999-02-11 1999-02-11 Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
ATA194/99 1999-02-11

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US09913400 A-371-Of-International 2000-02-01
US09/913,400 A-371-Of-International US6635246B1 (en) 1999-02-11 2000-02-01 Inactivated influenza virus vaccine for nasal or oral application
US10/639,449 Continuation US6861244B2 (en) 1999-02-11 2003-08-13 Inactivated influenza virus vaccine for nasal or oral application

Publications (2)

Publication Number Publication Date
WO2000047222A2 WO2000047222A2 (de) 2000-08-17
WO2000047222A3 true WO2000047222A3 (de) 2001-10-11

Family

ID=3483987

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AT2000/000023 WO2000047222A2 (de) 1999-02-11 2000-02-01 Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation

Country Status (10)

Country Link
US (4) US6635246B1 (de)
EP (1) EP1144001B1 (de)
AT (2) AT407958B (de)
AU (1) AU770923B2 (de)
CY (1) CY1108272T1 (de)
DE (1) DE50015170D1 (de)
DK (1) DK1144001T3 (de)
ES (1) ES2307494T3 (de)
PT (1) PT1144001E (de)
WO (1) WO2000047222A2 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL212316B1 (pl) * 1998-06-12 2012-09-28 Sinai School Medicine Zastosowania preparatów szczepionek, zastosowania preparatów farmaceutycznych oraz sposoby wytwarzania szczepionek
AT407958B (de) * 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
ATE376825T1 (de) * 1999-09-24 2007-11-15 Glaxosmithkline Biolog Sa Influenzavirus-impfstoffzusammensetzung zur nasalen anwendung
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US20030092145A1 (en) * 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
US9974847B2 (en) 2000-08-24 2018-05-22 Immunitor USA, Inc. Treatment and prevention of tuberculosis
CN102861325A (zh) * 2003-11-10 2013-01-09 Uab研究基金会 减少细菌携带和中枢神经系统侵害的组合物及其使用方法
DE202005022108U1 (de) 2004-03-09 2013-11-12 Novartis Vaccines And Diagnostics, Inc. Influenza-Virus-Impfstoffe
ES2694123T3 (es) 2004-06-01 2018-12-18 Icahn School Of Medicine At Mount Sinai Virus de la gripe porcina modificado por ingeniería genética y usos de los mismos
WO2006088481A2 (en) * 2005-02-15 2006-08-24 Mount Sinai School Of Medicine Of New York University Genetically engineered equine influenza virus and uses thereof
PT1861120T (pt) 2005-03-23 2016-08-18 Glaxosmithkline Biologicals Sa Utilização de um vírus influenza e de um adjuvante de emulsão óleo-em-água para induzir células t cd4 e/ou melhorar a resposta de células b de memória
PL2251034T3 (pl) 2005-12-02 2018-07-31 Icahn School Of Medicine At Mount Sinai Chimeryczne wirusy prezentujące nienatywne białka powierzchniowe i zastosowania tych wirusów
MX2009000660A (es) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.
CA2661210A1 (en) * 2006-08-17 2008-02-21 The Uab Research Foundation Diagnosing pneumococcal pneumonia
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
PE20090146A1 (es) 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
WO2008143676A1 (en) 2007-05-23 2008-11-27 The Uab Research Foundation Detoxified pneumococcal neuraminidase and uses thereof
KR100850545B1 (ko) * 2007-10-30 2008-08-05 주식회사 에니멀제네틱스 신규한 개 인플루엔자 바이러스 및 이의 백신
EP2278997B1 (de) * 2008-04-21 2016-08-10 Nanobio Corporation Nanoemulsions-grippeimpfstoff
US8647642B2 (en) 2008-09-18 2014-02-11 Aviex Technologies, Llc Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
EP2376628B1 (de) 2008-12-16 2018-05-16 Ology Bioservices, Inc. Erzeugung von impfstoffe gegen influenza virus
CN101524537B (zh) * 2009-03-26 2012-11-28 成都康华生物制品有限公司 流感口服含片疫苗、流感口服缓释疫苗以及二者制备方法
EP2413962A1 (de) 2009-03-30 2012-02-08 Mount Sinai School of Medicine Impfstoffe gegen das grippevirus und ihre verwendungen
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
US9849173B2 (en) 2009-07-06 2017-12-26 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
WO2011014504A1 (en) 2009-07-27 2011-02-03 Mount Sinai School Of Medicine Of New York University Recombinant influenza virus vectors and uses thereof
US8828406B2 (en) 2009-07-30 2014-09-09 Icahn School Of Medicine At Mount Sinai Influenza viruses and uses thereof
US20110110975A1 (en) * 2009-11-06 2011-05-12 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
BR112012022059B1 (pt) * 2010-03-02 2021-07-27 Applied Medical Enzyme Research Institute Corporation Vacina de mucosa produtora de uma iga de mucosa antígenoespecífica e igg do sangue e método para produzir uma vacina de mucosa
CA2792537A1 (en) 2010-03-30 2011-10-06 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
AU2011276223C1 (en) 2010-07-06 2016-05-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
MX359103B (es) 2011-01-13 2018-09-14 Variation Biotechnologies Inc Composiciones y sus usos en el tratamiento de infecciones virales.
EP2663288B1 (de) 2011-01-13 2022-12-21 Variation Biotechnologies Inc. Verfahren zur vesikelherstellung und darin hergestellte formulierungen
WO2012151391A2 (en) 2011-05-04 2012-11-08 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
US9492525B2 (en) 2011-07-06 2016-11-15 Nanobio Corporation Human respiratory syncytial virus vaccine
US20130189303A1 (en) 2011-08-02 2013-07-25 Yan Zhou Recombinant swine influenza virus and uses thereof
EP3329936A1 (de) 2011-08-22 2018-06-06 Nanobio Corporation Impfstoff gegen den herpes-simplex-virus als nanoemulsion
EP2758075B1 (de) 2011-09-20 2023-05-03 Icahn School of Medicine at Mount Sinai Influenzavirus-impfstoffe und verwendungen davon
EP2780350B1 (de) 2011-11-18 2019-03-06 Variation Biotechnologies Inc. Synthetische mpl-derivate und ihre verwendung
CN104302323A (zh) 2012-01-12 2015-01-21 变异生物技术公司 用于治疗病毒感染的组合物和方法
RU2698906C2 (ru) 2012-01-27 2019-09-02 Вэриэйшн Биотекнолоджиз, Инк. Способы и композиции для терапевтических агентов
JP2016508133A (ja) 2012-12-18 2016-03-17 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン及びその使用
WO2014164699A1 (en) * 2013-03-11 2014-10-09 The Regents Of The University Of California Herpes virus vaccines and treatments
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
JP2018504412A (ja) 2015-01-23 2018-02-15 アイカーン スクール オブ メディシン アット マウント サイナイ インフルエンザウイルスワクチン接種レジメン
CN107250353B (zh) 2015-02-26 2021-07-23 勃林格殷格翰动物保健有限公司 二价猪流感病毒疫苗
EP3471767A4 (de) 2016-06-15 2020-01-15 Icahn School of Medicine at Mount Sinai Influenzavirus-hämagglutinin-proteine und verwendungen davon
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
EP3606555A4 (de) 2017-04-07 2021-08-04 Icahn School of Medicine at Mount Sinai Neuraminidase-antikörper gegen influenza-b-virus und verwendungen davon
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
US20220370605A1 (en) 2019-10-08 2022-11-24 Luxembourg Institute Of Health (Lih) Inhibitor of DJ-1 for Use in Treating Immunoaging
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994019013A1 (en) * 1993-02-19 1994-09-01 Smithkline Beecham Corporation Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
WO1996040290A1 (en) * 1995-06-07 1996-12-19 Connaught Laboratories, Inc. Immunological combination compositions and methods
WO1997049423A2 (en) * 1996-06-24 1997-12-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal influenza vaccine composition and method
WO1999024068A1 (en) * 1997-11-10 1999-05-20 Michigan State University Immortal avian cell line to grow avian and animal viruses to produce vaccines
WO2000015251A2 (de) * 1998-09-15 2000-03-23 Baxter Aktiengesellschaft Influenzavirus-impfstoffzusammensetzung

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62201574A (ja) * 1986-02-27 1987-09-05 Shionogi & Co Ltd 家禽用インフルエンザワクチン
US4981782A (en) * 1987-05-14 1991-01-01 Sri International Synthetic peptides for diagnosis and prevention of influenza virus infection and their use
US5136019A (en) * 1989-05-24 1992-08-04 Sri International Synthetic peptides for diagnosis and prevention of influenza virus infection and their use
US5243030A (en) * 1989-05-24 1993-09-07 Sri International Conjugates of a synthetic peptide for diagnosis and prevention of influenza virus infection
US5562909A (en) * 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants
US5976552A (en) * 1995-04-28 1999-11-02 Protein Sciences Corporation Virus vaccines
JP3158157B2 (ja) * 1994-11-10 2001-04-23 バクスター・アクチエンゲゼルシャフト 無蛋白培養における生物製剤の製造法
US6949244B1 (en) * 1995-12-20 2005-09-27 The Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
US5690942A (en) * 1995-06-02 1997-11-25 American Home Products Corporation Adjuvants for viral vaccines
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994019013A1 (en) * 1993-02-19 1994-09-01 Smithkline Beecham Corporation Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
WO1996040290A1 (en) * 1995-06-07 1996-12-19 Connaught Laboratories, Inc. Immunological combination compositions and methods
WO1997049423A2 (en) * 1996-06-24 1997-12-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal influenza vaccine composition and method
WO1999024068A1 (en) * 1997-11-10 1999-05-20 Michigan State University Immortal avian cell line to grow avian and animal viruses to produce vaccines
WO2000015251A2 (de) * 1998-09-15 2000-03-23 Baxter Aktiengesellschaft Influenzavirus-impfstoffzusammensetzung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AVTUSHENKO S S ET AL: "Clinical and immunological characteristics of the emulsion form of inactivated influenza vaccine delivered by oral immunization", JOURNAL OF BIOTECHNOLOGY,NL,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 44, no. 1, 26 January 1996 (1996-01-26), pages 21 - 28, XP004036844, ISSN: 0168-1656 *

Also Published As

Publication number Publication date
ATE395929T1 (de) 2008-06-15
US20040096464A1 (en) 2004-05-20
US7052701B2 (en) 2006-05-30
EP1144001B1 (de) 2008-05-21
US20060147468A1 (en) 2006-07-06
US6635246B1 (en) 2003-10-21
AU2525300A (en) 2000-08-29
EP1144001A2 (de) 2001-10-17
WO2000047222A2 (de) 2000-08-17
DE50015170D1 (de) 2008-07-03
DK1144001T3 (da) 2008-09-15
PT1144001E (pt) 2008-08-29
US20050196413A1 (en) 2005-09-08
ES2307494T3 (es) 2008-12-01
AU770923B2 (en) 2004-03-11
AT407958B (de) 2001-07-25
ATA19499A (de) 2000-12-15
US6861244B2 (en) 2005-03-01
CY1108272T1 (el) 2014-02-12

Similar Documents

Publication Publication Date Title
WO2000047222A3 (de) Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
CA2201598A1 (en) Vaccine compositions
HUP0100058A1 (hu) LTB Adjuvánst tartalmazó vakcinák
NZ323973A (en) Vaccine compositions for intranasal administration comprising chitosan and use thereof
EP1878424A3 (de) Neuartiger Impfstoff
AU2001295673A1 (en) Vaccine composition
EP1618889B8 (de) Influenzavirus-Impfstoffzusammensetzung
WO2002072012A3 (en) A novel proteosome-liposaccharide vaccine adjuvant
WO2002028422A3 (en) Split enveloped virus preparation for intranasal delivery
ATE269341T1 (de) Verbindungen mit immunologischem adjuvanseffekt
WO2001060402A3 (en) Proteosome influenza vaccine
HUP9801560A1 (hu) Szaponint és szterint tartalmazó vakcinák
RU2000116260A (ru) Вакцины с адъювантом ltb
WO2000062801A3 (en) Combination vaccine against streptococcus pneumoniae and respiratory syncytial virus (rsv)
WO2005028496A3 (en) Vaccine for treatment and prevention of herpes simplex virus infection
AU2002221519A1 (en) Pharmaceutical compositions enhancing the immunogenicity of poorly immunogenic antigens
WO2003059385A3 (en) Hiv vaccine and method of use
WO2003089584A3 (en) Use of parapox b2l protein to modify immune responses to administered antigens
WO2001060404A3 (en) Use of opri lipoprotein from pseudomonas as a th1 inducing natural adjuvant for heterologous antigens
WO2003061692A3 (es) Antígeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes.
WO2001035993A3 (en) Compositions and methods for stimulating an immune response against infectious agents
JP2003514030A5 (de)
WO2001083528A3 (en) Nucleic acid immunization
WO2002070004A3 (en) Papillomavirus vaccines
CA2452008A1 (en) Ltb4 as vaccine adjuvant

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000903423

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 25253/00

Country of ref document: AU

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2000903423

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09913400

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2000903423

Country of ref document: EP